Enanta Pharmaceuticals Inc
enanta.comWhat Do They Do?
Develops small-molecule drugs for viral infections and immune-related diseases, and earns royalties from a hepatitis C treatment marketed by AbbVie.
10-K for FY2025, filed Nov 19, 2025We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop…View ↗
We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the…View ↗
In immunology, we are designing and developing highly potent and selective, oral small molecule inhibitors for the treatment of type 2…View ↗
HCV. Two protease inhibitors developed through our Collaborative Development and License Agreement with AbbVie have been clinically tested…View ↗
Since August 2017, substantially all of our royalty revenue has been derived from AbbVie’s net sales of MAVYRET/MAVIRET. Our ongoing…View ↗
How Do They Make Money?
AbbVie pays Enanta royalties based on sales of its hepatitis C combination treatment MAVYRET/MAVIRET; Enanta receives the royalties as the underlying sales are made. Enanta also received an upfront license payment for an antibacterial compound in fiscal 2023.
10-K for FY2025, filed Nov 19, 2025Glecaprevir is the HCV protease inhibitor we discovered that was developed by AbbVie in a fixed-dose combination with its NS5A inhibitor…View ↗
The Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the…View ↗
Our revenue is primarily derived from our collaboration agreement with AbbVie and AbbVie’s sales of MAVYRET/MAVIRET, an 8-week treatment…View ↗
-
10-K for FY2025, filed Nov 19, 2025
FY2025 revenue by product or service ↗
$65.3M
-
10-K for FY2025, filed Nov 19, 2025
$65.3M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Royalty
Licensed
10-K for FY2025, filed Nov 19, 2025 |
100%
FY2022: 100%
|
Royalty, FY2025
$65.3M Sources
|
Licensed |
|
License
Sold outright
|
0.0%
FY2022: 0.0%
|
License, FY2025
$0 Sources
|
Sold outright |
Who Are Their Customers?
AbbVie commercializes the HCV combination treatment that generates Enanta's royalty revenue. Enanta has no sales team and may work with larger pharmaceutical or biopharmaceutical companies to develop or commercialize its own drug candidates.
10-K for FY2025, filed Nov 19, 2025Our royalty revenue is generated through our Collaborative Development and License Agreement with AbbVie, under which we have discovered…View ↗
Glecaprevir is the HCV protease inhibitor we discovered that was developed by AbbVie in a fixed-dose combination with its NS5A inhibitor…View ↗
Sales and MarketingView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Aug 12, 2026
−$19.5MView ↗
- ▲ +7% (Loss)
- vs −$18.3M in Q3 FY2025
10-Q for Q3 FY2026, filed Aug 12, 2026
Open tableView ↗
-
Jun 23, 2026
Appeal court upheld invalidation of Enanta's patent in Pfizer case
The Federal Circuit affirmed the decision that the patent claims were invalid in the case over Pfizer's Paxlovid.
Sources
8-K, filed Jun 23, 2026
As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), the Company filed a notice of appeal with the United States Court…View ↗
-
Jun 18, 2026
Enanta advanced zelicapavir toward registrational testing for RSV
The company plans adult Phase 2b/3 and pediatric Phase 2b trials, with topline data expected in 2027.
Sources
8-K, filed Jun 18, 2026
Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027View ↗
Shrinking. Revenue fell 33% in 4 years, from $97.1M in FY2021 to $65.3M in FY2025, about 9% a year.
Expanded into immunology
The older report described research and development focused on viral infections. The latest report also describes oral drug programs for immune-related diseases.
10-K for FY2022, filed Nov 23, 2022 10-K for FY2025, filed Nov 19, 2025We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop…View ↗
In immunology, we are designing and developing highly potent and selective, oral small molecule inhibitors for the treatment of type 2…View ↗
Immunology. We are leveraging our expertise in developing inhibitors to design and develop highly potent and selective oral small molecule…View ↗
Who Do They Compete With?
Competes with Ark Biosciences, Shionogi, AstraZeneca, Sanofi, Merck, Pfizer, Moderna, and GSK
10-K for FY2025, filed Nov 19, 2025Several companies are seeking to develop antiviral treatments for RSV infection in adult and pediatric patients. Ark Biosciences and…View ↗
Loading...
